Sep. 3 at 2:17 PM
$RARE $BMRN This is a no brainer! I bet board at BioMarin pushes a buyout for
$RARE. This was the playbook of Tim W @ HZNP, bolt on acquisitions of Rare portfolio - AMGEN bought them for 27B!
Ultragenyx currently has 5 drugs on the market:
1 Crysvita — XLH and tumor-induced osteomalacia
2 Dojolvi — long-chain fatty-acid oxidation disorders
3 Mepsevii — MPS VII
4 Evkeeza — Ultragenyx markets it outside the U.S.; Regeneron USA
5 Genglycos — GSDIa gene therapy, FDA-approved August 19, 2026
